The purpose of this Phase 2a study is to evaluate the efficacy, safety and tolerability, of multiple parallel doses of PF-00734200 following oral administration to adult human subjects with T2DM who currently are on a stable dose of metformin.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
303
HbA1C levels (%)
Time frame: 12 weeks
Evaluation of Dose Response in HbA1c (%)
Time frame: 12 weeks
Insulin and Glucose AUC following a mixed meal tolerance test
Time frame: 12 weeks
Proportion of subjects achieving ADA glycemic goal of Hb A1c <7%
Time frame: 12 weeks
Incidence of Adverse Events
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
5 mg QD
2 mg QD
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Gilbert, Arizona, United States
Pfizer Investigational Site
Phoenix, Arizona, United States
Pfizer Investigational Site
Phoenix, Arizona, United States
Pfizer Investigational Site
Jonesboro, Arkansas, United States
Pfizer Investigational Site
Little Rock, Arkansas, United States
Pfizer Investigational Site
Carmichael, California, United States
Pfizer Investigational Site
Chula Vista, California, United States
Pfizer Investigational Site
Fair Oaks, California, United States
Pfizer Investigational Site
Los Angeles, California, United States
...and 69 more locations